ALBANY, N.Y., Oct. 22, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Steven R. Hagen, Ph.D., has been promoted to senior vice president of pharmaceutical development and manufacturing. He will continue to report to AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. Dr. Hagen is responsible for approximately two-thirds of AMRI's contract operations, including Chemical Development, Analytical and Pharmaceutical Quality Services, Small Scale cGMP Manufacturing of active ingredients and dosage forms, and Large Scale Commercial Manufacturing. These operations encompass facilities located in Albany, Rensselaer and Syracuse, New York; Burlington, Massachusetts; Holywell, Wales (UK) and Hyderabad and Aurangabad, India.
"We are pleased to announce this promotion of Dr. Hagen," said Dr. D'Ambra. "Under Dr. Hagen's leadership, AMRI has experienced growth within key sectors of AMRI's business. Additionally, Dr. Hagen has overseen the continued expansion and adherence to world class compliance programs and milestones, as well as the consistent attainment of operating performance metrics in AMRI's manufacturing area."
Dr. D'Ambra continued, "Steve has surrounded himself with a first class team and together they have continued to drive improvement and performance in our pharmaceutical services development and manufacturing operations and created industry leading quality compliance and project management functions. As a result, AMRI has been able to distinguish itself in Steve's areas of responsibility in a highly competitive marketplace and continues to cement relationships with multiple customers throughout the world as a partner of choice for their development and supply of a large number of exciting new medicines. I am confident Dr. Hagen will continue to deliver the leadership that is needed in order to enhance our SMARTSOURCING™ approach while continuing to improve profitability in these business sectors. We are pleased to recognize Steve's continuing contributions to AMRI with this promotion to Senior Vice President."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts